Treatment of Advance Gastric Cancer With Disulfiram
Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
Chemotherapy is generally needed for advanced gastric cancer, and cisplatin is the main
chemotherapy drug. However, there are many adverse reactions, including bone marrow
suppression, gastrointestinal reactions, renal toxicity and neurotoxicity. These adverse
reactions can affect the comfort and compliance of patients during treatment. At present, it
is necessary to reduce adverse reactions of cisplatin and increase the chemotherapy
sensitivity of gastric cancer to cisplatin. Recent studies have found that disulfiram has a
potential anti-tumor effect. The disulfiram has shown significant in vivo and in vitro
anti-tumor activity in preclinical studies, and has become a potential candidate drug for
tumor treatment as an adjuvant in various clinical trials. In this clinical study, cisplatin
combined with disulfiram is mainly used to treat advanced gastric cancer.
Phase:
N/A
Details
Lead Sponsor:
First People's Hospital of Hangzhou
Collaborators:
College of Pharmaceutical Sciences at Zhejiang University The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University